Recurrent Immune Checkpoint Inhibitor Hepatitis With Pembrolizumab Cessation: A Stubborn Case of Delayed-Onset, Steroid-Refractory Hepatotoxicity
Abstract
Immune checkpoint inhibitors such as pembrolizumab are increasingly used in cancer therapy, yet immune-related adverse events like immune-mediated liver injury from checkpoint inhibitors remain challenging to diagnose and manage. Most cases arise early in treatment and respond to corticosteroids, but rare delayed or refractory presentations have been described. We report a unique case of delayed-onset, steroid-refractory immune-mediated liver injury from checkpoint inhibitors requiring escalation of therapy despite prolonged discontinuation of the causative agent, highlighting the need for continued vigilance and individualized management strategies in patients receiving immune checkpoint inhibitors.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Hepatocellular Carcinoma Treatment and Prognosis
Management of metastatic bone disease
Publication details
- Journal / source
- ACG Case Reports Journal
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Volume
- 13
- Issue
- 4
- Pages
- e02050–e02050
- Publication date
- 30 March 2026
- Language
- EN